GHK-Cu topical vs injectable: where the evidence actually is (and isn't)
Topical GHK-Cu has decades of dermatology research and FDA cosmetic approval. Injectable has biohacker enthusiasm and Category 2 status. Very different evidence bases.
GHK-Cu (the copper-binding tripeptide glycyl-L-histidyl-L-lysine-copper) is used in two radically different ways. Topically — as a skincare and hair serum ingredient — it has decades of dermatology research, FDA cosmetic approval, and meaningful clinical evidence for wrinkle reduction and hair growth. Injectably — for systemic anti-aging and tissue repair — the human evidence is minimal and the substance sits on the FDA's Category 2 list as of September 2023.
| Field | Topical GHK-Cu | Injectable GHK-Cu |
|---|---|---|
| Brand names | various — e.g., The Ordinary Copper Peptides, NIOD CAIS | research-peptide vendors |
| Manufacturer | Various cosmetic manufacturers | Various research-peptide vendors |
| FDA approved | Permitted under FDA cosmetic regulation | Not FDA approved; Category 2 (Sep 2023); Feb 2026 HHS proposed removal |
| Indication | Cosmetic (wrinkle reduction, skin firmness, hair-growth serums) | Research use; biohacker claims for tissue repair, anti-aging |
| Mechanism | Collagen synthesis stimulation, antioxidant, hair-follicle stimulation | Same molecule as topical but systemic distribution |
| Delivery | Topical serum / lotion / scalp application | Subcutaneous injection (research use) |
Frequently asked
Is topical GHK-Cu actually proven to work?
Moderate evidence for specific outcomes. Peer-reviewed studies demonstrate improvements in wrinkle depth, skin firmness, and hair follicle stimulation with topical GHK-Cu formulations. Evidence is strongest for wrinkle/elasticity cosmetic outcomes and reasonable for hair-growth adjuncts.
Why is topical OK and injectable Category 2?
Topical use at cosmetic concentrations has decades of safety data and minimal systemic absorption. Injectable delivery creates systemic copper exposure, different pharmacokinetics, and poses regulatory and safety questions the FDA determined warrant review before compounding access.
Are there risks with chronic topical GHK-Cu use?
Generally well-tolerated; reported reactions include occasional irritation or photosensitivity at high concentrations. Copper toxicity from topical cosmetic doses has not been demonstrated in clinical data.
Where does the biohacker anti-aging case for injectable GHK-Cu come from?
From animal models and mechanistic studies (Pickart's gene-expression work and wound-healing animal data) extrapolated to humans without Phase 3 trial evidence. The translation is not rigorous. Meaningful human data at the systemic level is limited.